CLINICAL_TRIALS
ClinicalTrials.gov record update
Front-line Treatment of Philadelphia Positive/BCR-ABL Positive Acute Lymphoblastic Leukemia With Ponatinib, a New Potent Tyrosine Kinase Inhibitor.
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT01641107
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:38:23.213674+00:00
- Published At
- 2021-11-30T00:00:00+00:00
- Record Updated At
- 2021-11-30
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Philadelphia Positive", "BCR-ABL Positive", "Acute Lymphoblastic Leukemia"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2021-11-30"- protocolSection.identificationModule.nctId
"NCT01641107"- protocolSection.identificationModule.officialTitle
"Front-line Treatment of Philadelphia Positive/BCR-ABL Positive Acute Lymphoblastic Leukemia With Ponatinib, a New Potent Tyrosine Kinase Inhibitor."- protocolSection.statusModule.overallStatus
"COMPLETED"- protocolSection.designModule.phases
["PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.